Brief: UCB Says Bimzelx Achieves Inflammotory Lesion Resolution In Be Heard Trials

UCB SA

04/02/2026 06:12

Feb 4 (Reuters) - Ucb SA UCB.BR:

THREE-YEAR DATA FROM BE HEARD TRIALS FOR BIMZELX

DEMONSTRATED TOTAL RESOLUTION OF INFLAMMATORY LESIONS AND SUBSTANTIAL IMPROVEMENTS IN DISEASE SEVERITY, SUSTAINED TO THREE YEARS

Source text: https://tinyurl.com/2u8ajvvc

Further company coverage: UCB.BR

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))